David G. Lombardi, MD
University of Kentucky, Department of Obstetrics and Gynecology, Lexington, Ky.
Niki B. Istwan, RN
Matria Healthcare, Department of Clinical Research, Marietta, Ga.
Debbie J. Rhea, MPH
Matria Healthcare, Department of Clinical Research, Marietta, Ga.
John M. O'Brien, MD
Central Baptist Hospital, Division of Maternal-Fetal Medicine, Lexington, Ky.
John R. Barton, MD
Central Baptist Hospital, Division of Maternal-Fetal Medicine, Lexington, Ky.

In this study, outpatient management was effective in controlling nausea and vomiting during pregnancy and was associated with a reduced need for hospital or emergency room treatment as well as reduced costs.

David G. Lombardi, MD

University of Kentucky, Department of Obstetrics and Gynecology, Lexington, Ky.

Niki B. Istwan, RN

Matria Healthcare, Department of Clinical Research, Marietta, Ga.

Debbie J. Rhea, MPH

Matria Healthcare, Department of Clinical Research, Marietta, Ga.

John M. O'Brien, MD

Central Baptist Hospital, Division of Maternal-Fetal Medicine, Lexington, Ky.

John R. Barton, MD

Central Baptist Hospital, Division of Maternal-Fetal Medicine, Lexington, Ky.

ABSTRACT

Purpose: Nausea and vomiting during pregnancy (NVP) can create a significant clinical, psychological, and economic burden for patients, health care providers, and payers. The purpose of this analysis is to describe the clinical and economic outcomes of patients diagnosed with NVP utilizing an outpatient program of nursing support and pharmacologic treatment with subcutaneous metoclopramide (SMT).

Design: Women with singleton gestations who were experiencing NVP and whose physicians prescribed an outpatient program with SMT between January 2000 and February 2002 were identified from a database.

Methodology: Descriptive and statistical methods were used to analyze and report incidence of treatment failure, hospitalization/emergency room (ER) visits, degree of ketonuria, and Pregnancy-Unique Quantification of Emesis and Nausea (PUQE) score at program start/stop.

Principal findings: For a treatment duration of 26.9–20.8 days, 428 women were enrolled for outpatient SMT at 10.9–3.2 weeks' gestation. Improvement in NVP symptoms was achieved in 382 women with SMT (89.3 percent), while 46 (10.7 percent) required alteration of antiemetic therapy to subcutaneous ondansetron. The PUQE score at the start of SMT was 7.8–2.9, decreasing to 3.9–1.7 by therapy completion (P<.001). At treatment initiation, a PUQE score greater than or equal to 7 was reported by 63.1 percent of women versus 9.1 percent at the program's end (P<.001). Patients with ketonuria that was more than or equal to 1+ decreased from 36.2 percent to 1.4 percent (P<.001). The portion of patients with hospital/ER visits decreased from 65.4 percent to 3.3 percent during treatment (P<.001). Oral dietary improvement was noted in 78.7 percent of patients during treatment.

Conclusion: Outpatient management was effective in controlling NVP and was associated with a reduced need for hospital or emergency room treatment.

Author correspondence:
Niki Istwan, RN
Matria Healthcare
1850 Parkway Place
Marietta, GA 30067

This paper has undergone peer review by appropriate members of Managed Care's Editorial Advisory Board.

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.